The Brave study, scheduled for completion in September this year, involves serial spinal taps. These are invasive procedures....Since the study has not been stopped for futility, I assume that there are at least some positive results at this time and that the study is being continued to see if Brave can yield results closer to statistical significance.
With positive results from Brave, even though they may lack statistical significance, the FDA could IMO approve Vascepa, with its placebo like safety profile, for the treatment of such a debilitating condition as Alzheimers disease.
News 
Market Data 
Discover 
AI
